GAM
CHRS icon

Gotham Asset Management’s Coherus Oncology CHRS Stock Holding History

Gotham Asset Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-10,896
Closed -$174K – 1142
2021
Q4 		$174K Buy
10,896
+1
+0% +$17 0.01% 1089
2021
Q3 		$175K Sell
10,895
-726
-6% -$10.6K 0.01% 982
2021
Q2 		$161K Buy
11,621
+1,370
+13% +$19.4K 0.01% 959
2021
Q1 		$150K Buy
+10,251
New +$174K 0.01% 965
2020
Q4 		– Sell
-19,614
Closed -$360K – 1006
2020
Q3 		$360K Sell
19,614
-48,006
-71% -$893K 0.01% 804
2020
Q2 		$1.21M Sell
67,620
-68,875
-50% -$1.17M 0.04% 516
2020
Q1 		$2.21M Buy
136,495
+14,012
+11% +$259K 0.06% 388
2019
Q4 		$2.21M Buy
122,483
+104,968
+599% +$1.94M 0.04% 449
2019
Q3 		$355K Buy
+17,515
New +$350K 0.01% 870
2017
Q2 		– Sell
-36,380
Closed -$769K – 977
2017
Q1 		$769K Buy
36,380
+3,398
+10% +$83.6K 0.01% 708
2016
Q4 		$928K Buy
32,982
+15,619
+90% +$437K 0.01% 630
2016
Q3 		$465K Buy
+17,363
New +$474K 0.01% 720

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Gotham Asset Management's CHRS Position: Q1 2022 in Review

Gotham Asset Management sold out of Coherus Oncology (CHRS) in Q1 2022, closing a stake of 10,896 shares — an estimated $174K sold.

Gotham Asset Management first reported a position in CHRS in Q3 2016 and held it in 12 quarters. The position peaked at $2.21M in Q1 2020. 183 funds tracked by Wall St. Rank hold CHRS as of Q1 2022.

  • Gotham Asset Management reported no remaining Coherus Oncology position as of Q1 2022 after selling out during the quarter.
  • Gotham Asset Management sold 10,896 Coherus Oncology shares in Q1 2022, an estimated $174K.
  • Gotham Asset Management first reported a position in Coherus Oncology in Q3 2016 and held it in 12 quarters.
  • Gotham Asset Management's Coherus Oncology position peaked at $2.21M in Q1 2020.
  • 183 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2022.

Based on Gotham Asset Management's 13F filing for Q1 2022, filed 16 May 2022.